[go: up one dir, main page]

NO20030295L - Anvendelse av derivater av valproinsyre- og 2- valproensyreamider for behandling av manier ved bipolare lidelser - Google Patents

Anvendelse av derivater av valproinsyre- og 2- valproensyreamider for behandling av manier ved bipolare lidelser

Info

Publication number
NO20030295L
NO20030295L NO20030295A NO20030295A NO20030295L NO 20030295 L NO20030295 L NO 20030295L NO 20030295 A NO20030295 A NO 20030295A NO 20030295 A NO20030295 A NO 20030295A NO 20030295 L NO20030295 L NO 20030295L
Authority
NO
Norway
Prior art keywords
valproic acid
manners
derivatives
treatment
bipolar disorders
Prior art date
Application number
NO20030295A
Other languages
English (en)
Norwegian (no)
Other versions
NO20030295D0 (no
Inventor
Mitchell Shirvan
Meir Bialer
Original Assignee
Yissum Res Dev Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Res Dev Co filed Critical Yissum Res Dev Co
Publication of NO20030295L publication Critical patent/NO20030295L/no
Publication of NO20030295D0 publication Critical patent/NO20030295D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO20030295A 2000-07-21 2003-01-20 Anvendelse av derivater av valproinsyre- og 2- valproensyreamider for behandling av manier ved bipolare lidelser NO20030295D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22010200P 2000-07-21 2000-07-21
PCT/US2001/023116 WO2002007677A2 (fr) 2000-07-21 2001-07-20 Utilisation de derives d'acide valproique et d'amides d'acide 2-valproenique pour le traitement de la manie en cas de desordre bipolaire

Publications (2)

Publication Number Publication Date
NO20030295L true NO20030295L (no) 2003-01-20
NO20030295D0 NO20030295D0 (no) 2003-01-20

Family

ID=22822065

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20030295A NO20030295D0 (no) 2000-07-21 2003-01-20 Anvendelse av derivater av valproinsyre- og 2- valproensyreamider for behandling av manier ved bipolare lidelser

Country Status (16)

Country Link
US (2) US6555585B2 (fr)
EP (1) EP1303289A4 (fr)
JP (1) JP2004520263A (fr)
KR (1) KR100843703B1 (fr)
CN (1) CN1251758C (fr)
AU (1) AU2001280699A1 (fr)
CA (1) CA2416821A1 (fr)
CZ (1) CZ2004266A3 (fr)
HU (1) HUP0600526A2 (fr)
IL (1) IL153942A0 (fr)
MX (1) MXPA03000547A (fr)
NO (1) NO20030295D0 (fr)
NZ (1) NZ523917A (fr)
PL (1) PL365588A1 (fr)
WO (1) WO2002007677A2 (fr)
ZA (1) ZA200300641B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004520263A (ja) * 2000-07-21 2004-07-08 テバ　ファーマシューティカル　インダストリーズ　リミティド 双極性障害における躁病を治療するためのバルプロ酸および２−バルプロエン酸アミド誘導体の使用
US20060223888A1 (en) * 2002-12-16 2006-10-05 Abbott Frank S Valproic acid analogues and pharmaceutical composition thereof
WO2004071424A2 (fr) * 2003-02-05 2004-08-26 Teva Pharmaceutical Industries, Ltd. Preparation de n-(2-propylpentanoyl)glycinamide a liberation immediate
WO2004071421A2 (fr) * 2003-02-05 2004-08-26 Teva Pharmaceutical Industries Ltd. Formule a liberation continue de n-(2-propylpentanoyl) glycinamide, et composes associes
IL157751A0 (en) * 2003-02-28 2004-03-28 Yissum Res Dev Co New amide derivatives of 2,2,3,3-tetramethylcyclopropane carboxylic acid, a method for their synthesis and pharmaceutical compositions containing them
IL156203A0 (en) * 2003-05-29 2003-12-23 Yissum Res Dev Co Use of 2,2,3,3, tetramethylcyclopropane carboxylic acid derivatives for treating psychiatric disorders
EP1491188A1 (fr) * 2003-06-25 2004-12-29 G2M Cancer Drugs AG Utilisation topique de l'acide valproique pour traiter des maladies de la peau
US20060004098A1 (en) * 2003-07-28 2006-01-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compounds useful for treating neurological disorders
EP1713486A4 (fr) * 2003-12-02 2009-04-29 Sheldon Leslie James Therapie combinee pour le traitement de la demence, la depression et l'apathie
US20060025477A1 (en) * 2004-07-22 2006-02-02 Artman Linda D Analogs of isovaleramide, a pharmaceutical composition including the same, and a method of treating central nervous system conditions or diseases
EP1928807A4 (fr) * 2005-09-02 2011-05-04 Picobella Llc Arn regulateurs oncogenes pour le diagnostic et la therapie
US7459280B2 (en) * 2006-02-27 2008-12-02 Picobella, Llc Methods for diagnosing and treating kidney cancer
US20080267977A1 (en) * 2007-04-26 2008-10-30 Friedrich-Alexander University Of Erlangen-Nuremberg Combined immunological agent and sensitizing agent for the treatment of cancer
CN106715695B (zh) 2014-02-05 2020-07-31 耶达研究及发展有限公司 用于治疗和诊断的微rna和包含所述微rna的组合物
KR102635938B1 (ko) * 2016-12-14 2024-02-13 에스케이바이오팜 주식회사 양극성 장애의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도
IL282188A (en) 2021-04-08 2022-11-01 Yeda Res & Dev Combined use of ketamine and bretigabine for the treatment of psychiatric disorders

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU988188A3 (ru) 1973-12-14 1983-01-07 Эсакмадьяросаги Ведьимювек (Инопредприятие) Способ получени N,N-дизамещенных амидов карбоновых кислот
DE3010599A1 (de) 1979-03-22 1980-10-09 Continental Pharma Derivate von glycinamid, deren herstellung und verwendung
US4301176A (en) * 1980-08-18 1981-11-17 Warner-Lambert Company Method of administering calcium valproate
FR2489319A1 (fr) * 1980-08-27 1982-03-05 Clin Midy Derives de l'acide amino-4 butyrique et les medicaments, actifs notamment sur le systeme nerveux central, en contenant
BE885303A (fr) 1980-09-19 1981-03-19 Continental Pharma Glycinamides
LU83729A1 (fr) * 1981-11-04 1983-09-01 Galephar Sels d'acide valproique,leur preparation et leur utilisation
DK373383A (da) 1982-08-20 1984-02-21 Midit Fremgangsmaade til fremstilling af omega-aminosyrederivater
US4913906B1 (en) 1985-02-28 2000-06-06 Yissum Res Dev Co Controlled release dosage form of valproic acid
IT1190133B (it) 1986-06-19 1988-02-10 Chiesi Farma Spa Derivati di acido valproico e di acido (e)-2-valproenoico,procedimento per la loro preparazione e relative composizioni farmaceutiche
WO1988001861A1 (fr) 1986-09-17 1988-03-24 Baxter Travenol Laboratories, Inc. Apport nutritionnel ou therapie pour personnes susceptibles de souffrir de maladies atherosclereuses, vasculaires, cardiovasculaires et/ou thrombotiques ou en traitement pour ces maladies
US5169642A (en) * 1988-06-24 1992-12-08 Abbott Laboratories Sustained-release drug dosage units
US6287598B1 (en) * 1993-05-28 2001-09-11 Alza Corporation Method for providing sustained antiepileptic therapy
US5585358A (en) * 1993-07-06 1996-12-17 Yissum Research Development Corporation Of The Hebrew University Of Jerusalem Derivatives of valproic acid amides and 2-valproenoic acid amides, method of making and use thereof as anticonvulsant agents
CZ296263B6 (cs) 1996-03-25 2006-02-15 Eli Lilly And Company Farmaceutická kompozice pro lécení bolesti a jejípouzití
IL121268A0 (en) 1997-07-09 1998-01-04 Dpharm Ltd Branched chain fatty acids their derivatives and use in the treatment of central nervous system disorders
WO1999066920A1 (fr) 1998-06-22 1999-12-29 American Biogenetic Sciences, Inc. Utilisation d'un analogue d'acide valproique dans le traitement et la prevention de migraine et de maladies affectives
JP2004520263A (ja) * 2000-07-21 2004-07-08 テバ　ファーマシューティカル　インダストリーズ　リミティド 双極性障害における躁病を治療するためのバルプロ酸および２−バルプロエン酸アミド誘導体の使用

Also Published As

Publication number Publication date
CA2416821A1 (fr) 2002-01-31
PL365588A1 (en) 2005-01-10
KR100843703B1 (ko) 2008-07-04
AU2001280699A1 (en) 2002-02-05
IL153942A0 (en) 2003-07-31
NZ523917A (en) 2004-11-26
EP1303289A2 (fr) 2003-04-23
NO20030295D0 (no) 2003-01-20
US6555585B2 (en) 2003-04-29
US20020103237A1 (en) 2002-08-01
EP1303289A4 (fr) 2009-08-05
JP2004520263A (ja) 2004-07-08
CN1251758C (zh) 2006-04-19
MXPA03000547A (es) 2004-04-05
HUP0600526A2 (en) 2006-11-28
WO2002007677A3 (fr) 2002-05-30
WO2002007677A2 (fr) 2002-01-31
CZ2004266A3 (cs) 2005-02-16
CN1446097A (zh) 2003-10-01
KR20030036610A (ko) 2003-05-09
US20030212142A1 (en) 2003-11-13
ZA200300641B (en) 2004-01-26

Similar Documents

Publication Publication Date Title
DE60023128D1 (de) Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
NO20030295D0 (no) Anvendelse av derivater av valproinsyre- og 2- valproensyreamider for behandling av manier ved bipolare lidelser
NO20001754L (no) Prostaglandinagonister og anvendelse derav for behandling av benforstyrrelser
NO20022585D0 (no) Pyrrolidinacetamidderivat alene eller i kombinasjon for behandling av CNS-forstyrrelser
AU9287401A (en) Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders
AU2002221881A1 (en) Carboxylic acid amide derivatives and their use in the treatment of thromboembolic diseases and tumours
ATE455106T1 (de) Acyl derivate zur behandlung von krankheiten die in zusammenhang mit vla-4 stehen
NO20041588L (no) Anvendelse av flibanserin ved behandling av seksuelle forstyrrelser
PL355998A1 (en) Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
EE04854B1 (et) Oksabispidiinühendid, nende valmistamise meetod ning ravimvorm kasutamiseks südame arütmia raviks ja profülaktikaks
NO20031903L (no) Nye amidoalkylpiperidin- og amidoalkylpiperazinderivater for anvendelse vedbehandling av nervesystemlidelser
PL356784A1 (pl) Substancja do zastosowania w leczeniu łuszczycy
NO20024924D0 (no) Anvendelse av bradykardiale substanser ved behandling av myokardiale sykdommer i forbindelse med hypertrofi og nyemedikamentkombinasjoner
NO20001412D0 (no) Sammensetninger og fremgangsmåter ved behandling av respiratoriske forstyrrelser
NO20032340D0 (no) Substituerte derivater av aminofuran-2-yl-eddiksyre og aminotien-2-yl-eddiksyre og deres anvendelse for behandling av migrene og smerte
DE60017133D1 (de) Naphthochinonderivate und ihre verwendung zur behandlung und kontrolle von tuberkulose
NO20006506D0 (no) Anvendelse av valproinsyreanalog for behandlingen og forebyggelsen av migrene og affektive sykdommer
AU2002220735A1 (en) Substituted derivatives of aminofuran-2-yl-acetic acid and aminothien-2-yl-acetic acid and the use thereof for treating migraines and pain
ATE323685T1 (de) Dihydrobenzodiazepinen und deren verwendung zur behandlung von dyslipidämien
ITMI20010957A0 (it) Derivati dell'aoe-emodina e loro impiego nel trattamento di patologieneoplastiche
EP1330271A4 (fr) Utilisation de facteurs de transcription dans le traitement d'inflammation et d'autres maladies
GB0007217D0 (en) Materials and methods relating to the treatment of leukaemias
EE200100527A (et) Osanetandi kasutamine meeleoluhäirete raviks kasulike ravimite valmistamiseks
EP1150669A4 (fr) Formulations a base de l-arginine utilisees dans le traitement de maladies, et leurs procedes d'utilisation
NO985974D0 (no) Piperidineddiksyrederivater og deres anvendelse ved behandling av trombose-sykdommer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application